About Botanix Pharmaceuticals (ASX:BOT)
Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. Its products include BTX1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne. The company is based in Northbridge, Australia.
Industry, Sector and Symbol
Trailing P/E Ratio-12
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Botanix Pharmaceuticals (ASX:BOT) Frequently Asked Questions
What is Botanix Pharmaceuticals' stock symbol?
Botanix Pharmaceuticals trades on the ASX under the ticker symbol "BOT."
Who are some of Botanix Pharmaceuticals' key competitors?
Who are Botanix Pharmaceuticals' key executives?
Botanix Pharmaceuticals' management team includes the folowing people:
- Graham Griffiths, Chairman of the Board
- William Bosch, Executive Director
- Matthew Callahan, Executive Director
- Simon L. Robertson, Company Secretary
- Robert E. T. Towner, Director
What is Botanix Pharmaceuticals' stock price today?
One share of Botanix Pharmaceuticals stock can currently be purchased for approximately A$0.12.
How big of a company is Botanix Pharmaceuticals?
Botanix Pharmaceuticals has a market capitalization of $46.40 million.
How can I contact Botanix Pharmaceuticals?
Botanix Pharmaceuticals' mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.
MarketBeat Community Rating for Botanix Pharmaceuticals (BOT)MarketBeat's community ratings are surveys of what our community members think about Botanix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Botanix Pharmaceuticals (ASX:BOT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Botanix Pharmaceuticals (ASX:BOT)
No earnings announcements for this company have been tracked by MarketBeat.com
Botanix Pharmaceuticals (ASX:BOT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Botanix Pharmaceuticals (ASX:BOT)
No dividend announcements for this company have been tracked by MarketBeat.com
Botanix Pharmaceuticals (ASX BOT) Insider Trading and Institutional Ownership History
Botanix Pharmaceuticals (ASX BOT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/19/2018||David John Garland||Director||Sell||350,000||A$0.16||A$56,000.00|
Botanix Pharmaceuticals (ASX BOT) News Headlines
Botanix Pharmaceuticals (ASX:BOT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Botanix Pharmaceuticals (ASX BOT) Stock Chart for Friday, February, 23, 2018